TITLE

QUARTERLY REPORTS

PUB. DATE
March 2011
SOURCE
Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p61
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to quarterly reports of various ocular companies ending March 25, 2011. Alimera Sciences has reported a fourth-quarter net loss of $6.3 million on its FAME study. Carl Zeiss Meditec has reported a €185.2 million consolidated revenue during the first quarter of 2010-2011. Inspire Pharmaceuticals has announced its plan to start a strategic corporate restructuring program which aims to focus on the eye care interests of the company.
ACCESSION #
86439119

 

Related Articles

  • Industry Pipeline.  // Ocular Surgery News;5/25/2010, Vol. 28 Issue 10, p26 

    This section offers news briefs related to the ophthalmic business including the granting by the U.S. Food and Drug Administration of an orphan drug status to Advanced Cell Technology Inc. for its MA09-hRPE cells for treatment of Stargardt's macular dystrophy and the FDA approval received by...

  • Eyes on New Product Development. Novack, Gary D. // Journal of Ocular Pharmacology & Therapeutics;Nov2013, Vol. 29 Issue 9, p785 

    The article discusses new ophthalmic products as of November 2013, including a fluocinolone acetonide drug by Alimera approved in France, aflibercept drugs by Regeneron and Bayer approved in Great Britain, and U.S. Food and Drug Administration review of an ocular hydrogel by Ocular Therapeutix.

  • MOVERS & SHAKERS.  // Ocular Surgery News;3/25/2013, Vol. 31 Issue 6, p50 

    The article announces several appointments and promotions in ophthalmology including Michael Irving as vice president of sales at Eyemaginations, Jeff Castillo as divisional vice president of commercial operations at Abbott Medical Optics and Robert Bertolini as president and chief financial...

  • MOVERS & SHAKERS. Kahl, Kristie L.; Te, Nhu // Ocular Surgery News;1/25/2015, Vol. 33 Issue 2, p38 

    The article announces several personnel changes in including appointment of Dale Fajardo as vice president (VP) for education at the American Academy of Ophthalmology, Paul Navarre as executive VP at drug company Actavis Inc. and Angela Bedell as executive director at Ophthalmic Women Leaders.

  • MOVERS & SHAKERS. Nhu Te // Ocular Surgery News;6/25/2014, Vol. 32 Issue 12, p34 

    This section offers news briefs on ophthalmology. Visionary Award from the American Academy of Ophthalmology were presented to 8 members of Congress which include Representatives Bill Flores of Texas, Dan Maffei of New York, and Larry Bucshon of Indiana. Appointments of key people are also...

  • MOVERS & SHAKERS. DiPietro, Cheryl // Ocular Surgery News;6/25/2013, Vol. 31 Issue 12, p50 

    The article announces the appointment of Doctor Donald Gagliano as vice president of global development operations of Bausch + Lomb, the nomination of Vicente Anido Jr. to the corporate board of Nicox, and the recognition of Representative Marsha Blackburn for promoting eye health.

  • MOVERS & SHAKERS. Nhu Te // Ocular Surgery News;7/25/2014, Vol. 32 Issue 14, p30 

    The article announces several appointments including Dietrich Wolf as chief executive officer (CEO) at EyeTechCare, Charles Semba as chief medical officer (CMO) at ForSight Vision5, and also informs that Agnes Wong has received 2014 Joanne Angle Investigator Award from Prevent Blindness.

  • MOVERS & SHAKERS. Kahl, Kristie L. // Ocular Surgery News;9/25/2014, Vol. 32 Issue 18, p48 

    The article announces career developments involving executives in the ophthalmic business, including the appointment of Mark Weinberg as senior vice president of clinical development at biopharmaceutical firm RestorGenex, Jim Hindman who was named executivevice president, finance and business...

  • MOVERS & SHAKERS.  // Ocular Surgery News;1/25/2013, Vol. 31 Issue 2, p40 

    The article announces that a management team including Philip Ashman, PHD; Eric Teo, MBBS; and Jim Mazzo, was appointed by Alimera Sciences Inc., a biopharmaceutical company, to look after European commercialization of Illuvien, a drug to treat diabetic macular edema.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics